Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel–Lindau protein
The DOI matches its Crossref record; 20 of the 21 references it cites were found in a registry or an index.
Abstract
von Hippel-Lindau (VHL) disease is a hereditary cancer syndrome that is characterized by the development of multiple vascular tumors and is caused by inactivation of the von Hippel-Lindau protein (pVHL). Here we show that pVHL, through its beta-domain, binds directly to hypoxia-inducible factor (HIF), thereby targeting HIF for ubiquitination in an alpha-domain-dependent manner. This is the first function to be ascribed to the pVHL beta-domain. Furthermore, we provide the first direct evidence that pVHL has a function analogous to that of an F-box protein, namely, to recruit substrates to a ubiquitination machine. These results strengthen the link between overaccumulation of HIF and development of VHL disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the presence of oxygen (typically > 5% O2), the HIF-α subunit is hydroxylated by PHDs in an iron and oxygen dependent manner, which leads to HIF-α polyubiquitination by pVHL, targeting HIF-α for proteasomal degradation (Figure 2) [8].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [8]
In the citing paper
“As described in the AdPROM section, VHL acts as the substrate receptor for the Cul2-Rbx1 E3 ligase complex, recruiting HIF1α for its ubiquitination and degradation [88].”
From Advances in targeted degradation of endogenous proteins (2019) · cites this paper as [88]
Citations
Cites
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
Huang, L. E., Gu, J., Schau, M., & Bunn, H. F. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.14.7987 · Cited by 2,113
Mitochondrial reactive oxygen species trigger hypoxia-induced transcription
Chandel, N. S., Maltepe, E., Goldwasser, E., Mathieu, C. E., Simon, M. C., & Schumacker, P. T. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.20.11715 · Cited by 1,926 · cited 1×
“Whether hypoxia and desferroxamine utilize the same molecular mechanism(s) to stabilize HIF in vivo remains to be determine”
BackgroundSalceda, S., & Caro, J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.36.22642 · Cited by 1,674
Structure of the VHL-ElonginC-ElonginB Complex: Implications for VHL Tumor Suppressor Function
Stebbins, C. E., Kaelin, W. G., & Pavletich, N. P. (1999) · Science · doi:10.1126/science.284.5413.455 · Cited by 860
Self-citationStabilization of wild-type p53 by hypoxia-inducible factor 1α
An, W. G., Kanekal, M., Simon, M. C., Maltepe, E., Blagosklonny, M. V., & Neckers, L. M. (1998) · Nature · doi:10.1038/32925 · Cited by 827
Regulation of the Hypoxia-inducible Transcription Factor 1α by the Ubiquitin-Proteasome Pathway
Kallio, P. J., Wilson, W. J., O'Brien, S., Makino, Y., & Poellinger, L. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.10.6519 · Cited by 754
Tumour suppression by the human von Hippel-Lindau gene product
Iliopoulos, O., Kibel, A., Gray, S., & Kaelin, W. G. (1995) · Nature Medicine · doi:10.1038/nm0895-822 · Cited by 703
Self-citationBinding of the von Hippel-Lindau Tumor Suppressor Protein to Elongin B and C
Kibel, A., Iliopoulos, O., DeCaprio, J. A., & Kaelin, W. G. (1995) · Science · doi:10.1126/science.7660130 · Cited by 671 · cited 1×
“pVHL normally exists in cells as a complex with elongin B and elongin C rather than as a monome”
BackgroundSelf-citationKamura, T., Sato, S., Haque, D., Liu, L., Kaelin, W. G., Conaway, R. C., & Conaway, J. W. (1998) · Genes & Development · doi:10.1101/gad.12.24.3872 · Cited by 595 · cited 1×
“pVHL normally exists in cells as a complex with elongin B and elongin C rather than as a monome”
BackgroundSelf-citation
Cited by
Items 201–300 of 1,005
Flügel, D., Görlach, A., & Kietzmann, T. (2012) · Blood · doi:10.1182/blood-2011-08-375014 · Cited by 191
Gao, N., Ding, M., Zheng, J. Z., Zhang, Z., Leonard, S. S., Liu, K. J., Shi, X., & Jiang, B.-H. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200082200 · Cited by 191
Hypoxia Inducible Factor-1 as a Target for Neurodegenerative Diseases
Zhang, Z., Yan, J., Chang, Y., ShiDu Yan, S., & Shi, H. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711797200426 · Cited by 189
Gunaratnam, L., Morley, M., Franovic, A., de Paulsen, N., Mekhail, K., Parolin, D. A. E., Nakamura, E., Lorimer, I. A. J., & Lee, S. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m305502200 · Cited by 188
Reactive oxygen species and cellular oxygen sensing
Cash, T. P., Pan, Y., & Simon, M. C. (2007) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2007.07.001 · Cited by 188
de Paulsen, N., Brychzy, A., Fournier, M.-C., Klausner, R. D., Gnarra, J. R., Pause, A., & Lee, S. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.4.1387 · Cited by 187
Groulx, I., & Lee, S. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.15.5319-5336.2002 · Cited by 187
Redox regulation of the hypoxia-inducible factor
Pouysségur, J., & Mechta-Grigoriou, F. (2006) · Biological Chemistry · doi:10.1515/bc.2006.167 · Cited by 186
Stickle, N. H., Chung, J., Klco, J. M., Hill, R. P., Kaelin, W. G., & Ohh, M. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.8.3251-3261.2004 · Cited by 185
Self-citationHIFs and tumors—causes and consequences
Höpfl, G., Ogunshola, O., & Gassmann, M. (2004) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00538.2003 · Cited by 185
“The loss or mutation of pVHL in vivo stabilizes the HIF-1 protein under normoxic conditions and may lead to the VHL hereditary cancer syndrome (41, 130, 145, 181, 257).”
Backgroundİlie, M., Mazure, N. M., Hofman, V, Ammadi, R. E., Ortholan, C., Bonnetaud, C., Havet, K., Venissac, N., Mograbi, B., Mouroux, J., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605690 · Cited by 184
“The expression of CAIX is strongly upregulated by hypoxia and is downregulated by the wild-type von Hippel-Lindau (pVHL) tumour suppressor protein (Ohh et al, 2000).”
Berra, E., Roux, D., Richard, D. E., & Pouysségur, J. (2001) · EMBO reports · doi:10.1093/embo-reports/kve130 · Cited by 183
Hypoxic Tumor Microenvironment and Cancer Cell Differentiation
Kim, Y., Lin, Q., Glazer, P., & Yun, Z. (2009) · Current Molecular Medicine · doi:10.2174/156652409788167113 · Cited by 183
Mutation of von Hippel–Lindau Tumour Suppressor and Human Cardiopulmonary Physiology
Smith, T. G., Brooks, J. T., Balanos, G. M., Lappin, T. R., Layton, D. M., Leedham, D. L., Liu, C., Maxwell, P. H., McMullin, M. F., McNamara, C. J., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030290 · Cited by 182
Koh, M. Y., Darnay, B. G., & Powis, G. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00773-08 · Cited by 182
The regulation of trophoblast differentiation by oxygen in the first trimester of pregnancy
James, J. L., Stone, P. R., & Chamley, L. W. (2006) · Human Reproduction Update · doi:10.1093/humupd/dmi043 · Cited by 182
“Under physiologically normoxic conditions HIF-α is rapidly broken down following binding of von Hippel-Lindau tumour suppressor protein (pVHL), which targets HIF-α for degradation by the ubiquitin-proteasome pathway (Figure 1) (Maxwell et al., 1999; Cockman et al., 2000; Ohh et al., 2000).”
BackgroundRegulation of human metabolism by hypoxia-inducible factor
Formenti, F., Constantin-Teodosiu, D., Emmanuel, Y., Cheeseman, J., Dorrington, K. L., Edwards, L. M., Humphreys, S. M., Lappin, T. R. J., McMullin, M. F., McNamara, C. J., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1002339107 · Cited by 182
“Forearm muscle blood flow was assessed by strain-gauge plethysmography (7).”
BackgroundMethodPantuck, A. J., Zeng, G., Belldegrun, A. S., & Figlin, R. A. (2003) · PubMed · Cited by 182
Functions of the aryl hydrocarbon receptor (AHR) beyond the canonical AHR/ARNT signaling pathway
Sondermann, N. C., Faßbender, S., Hartung, F., Hätälä, A. M., Rolfes, K. M., Vogel, C. F. A., & Haarmann-Stemmann, T. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115371 · Cited by 181
Bao, B., Azmi, A. S., Ali, S., Ahmad, A., Li, Y., Banerjee, S., Kong, D., & Sarkar, F. H. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.04.008 · Cited by 180
“and proteasome-dependent pathway [83,85-90], leading to the inactivation HIF-1α [88,91].”
BackgroundMu, D., Jiang, X., Sheldon, R. A., Fox, C. K., Hamrick, S. E. G., Vexler, Z. S., & Ferriero, D. M. (2003) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.08.020 · Cited by 179
“Thus HIF-1 is degraded through the ubiquitin protein path (An et al., 1998; Ohh et al., 2000; Tanimoto et al., 2000).”
BackgroundThe ubiquitin system, disease, and drug discovery
Petroski, M. D. (2008) · BMC Biochemistry · doi:10.1186/1471-2091-9-s1-s7 · Cited by 178
“The protein encoded by the tumor suppressor gene VHL (von Hippel-Lindau) serves as a substrate receptor for a CUL2-based ubiquitin ligase [50,75-80].”
BackgroundSotgia, F., Martinez-Outschoorn, U. E., Pavlides, S., Howell, A., Pestell, R. G., & Lisanti, M. P. (2011) · Breast Cancer Research · doi:10.1186/bcr2892 · Cited by 177
“About half of clear cell renal carcinomas are due to mutations in the Von Hippel-Lindau (VHL) gene [44,45], leading to HIF1α constitutive activation and forced induction of aerobic glycolysis [46-48].”
BackgroundAn intact NEDD8 pathway is required for Cullin‐dependent ubiquitylation in mammalian cells
Ohh, M., Kim, W. Y., Moslehi, J. J., Chen, Y., Chau, V., Read, M. A., & Kaelin, W. G. (2002) · EMBO reports · doi:10.1093/embo-reports/kvf028 · Cited by 177
“Immunoprecipitation and immunoblotting were performed as described previously (Ohh et al., 2000).”
MethodSelf-citationNQO1 inhibits proteasome-mediated degradation of HIF-1α
Oh, E.-T., Kim, J.-W., Kim, J. M., Kim, S. J., Lee, J.-S., Hong, S.-S., Goodwin, J., Ruthenborg, R. J., Jung, M. G., Lee, H.-J., et al. (2016) · Nature Communications · doi:10.1038/ncomms13593 · Cited by 176
Okuda, H., Saitoh, K., Hirai, S.-I., Iwai, K., Takaki, Y., Baba, M., Minato, N., Ohno, S., & Shuin, T. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m107880200 · Cited by 176
The VHL tumor suppressor: master regulator of HIF
Haase, V. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209789649394 · Cited by 175
The suppressors of cytokine signalling (SOCS)
Kile, B. T., & Alexander, W. S. (2001) · Cellular and Molecular Life Sciences · doi:10.1007/pl00000801 · Cited by 175
HIF hydroxylation and cellular oxygen sensing
Metzen, E., & Ratcliffe, P. J. (2004) · Biological Chemistry · doi:10.1515/bc.2004.016 · Cited by 172
“Further analysis demonstrated that pVHL is the substrate recognition component of a multi-protein E3 ubiquitin ligase and thus initiates polyubiqutination and proteasomal destruction of HIF-a subunits (Cockman et al., 2000; Ohh et al., 2000; Tanimoto et al., 2000).”
BackgroundChen, W., Wu, P., Yu, F., Luo, G., Qing, L., & Tang, J. (2022) · Cells · doi:10.3390/cells11223552 · Cited by 181
Protein neddylation and its role in health and diseases
Zhang, S., Yu, Q., Li, Z., Zhao, Y., & Sun, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01800-9 · Cited by 171
Yao, M., Tabuchi, H., Nagashima, Y., Baba, M., Nakaigawa, N., Ishiguro, H., Hamada, K., Inayama, Y., Kishida, T., Hattori, K., et al. (2005) · The Journal of Pathology · doi:10.1002/path.1693 · Cited by 171
A network medicine approach to human disease
Zanzoni, A., Soler-López, M., & Aloy, P. (2009) · FEBS Letters · doi:10.1016/j.febslet.2009.03.001 · Cited by 171
HIF-1-Independent Mechanisms Regulating Metabolic Adaptation in Hypoxic Cancer Cells
Lee, S.-H., Golinska, M., & Griffiths, J. R. (2021) · Cells · doi:10.3390/cells10092371 · Cited by 169
Rac1 Activity Is Required for the Activation of Hypoxia-inducible Factor 1
Hirota, K., & Semenza, G. L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100677200 · Cited by 168
Alterations in VHL as potential biomarkers in renal-cell carcinoma
Gossage, L., & Eisen, T. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.42 · Cited by 167
Molecular Diagnosis and Therapy of Kidney Cancer
Linehan, W. M., Bratslavsky, G., Pinto, P. A., Schmidt, L. S., Neckers, L., Bottaro, D. P., & Srinivasan, R. (2010) · Annual Review of Medicine · doi:10.1146/annurev.med.042808.171650 · Cited by 167
Goodwin, J., Choi, H., Hsieh, M.-H., Neugent, M. L., Ahn, J.-M., Hayenga, H. N., Singh, P. K., Shackelford, D. B., Lee, I.-K., Shulaev, V., et al. (2018) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2016-0186oc · Cited by 166
Dietary hyperglycemia, glycemic index and metabolic retinal diseases
Chiu, C.-J., & Taylor, A. (2011) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2010.09.001 · Cited by 156
“, 1999), becomes ubiquitinated, and is degraded via the proteasomal pathway (Cockman et al., 2000; Kamura et al., 2000; Lisztwan et al., 1999; Ohh et al., 2000; Tanimoto et al., 2000).”
Kaluz, S., Kaluzová, M., & Stanbridge, E. J. (2008) · Clinica Chimica Acta · doi:10.1016/j.cca.2008.05.002 · Cited by 165
“VHL has two subdomains, a and b, binding directly to elongin C and HIF-α, respectively [21].”
BackgroundHypoxia-induced Angiogenesis during Carcinogenesis
Choe, G.-S., Bae, M.-G., Jeong, J.-W., Mun, H.-E., & Kim, G.-W. (2003) · BMB Reports · doi:10.5483/bmbrep.2003.36.1.120 · Cited by 165
Oehme, F., Ellinghaus, P., Kolkhof, P., Smith, T. J., Ramakrishnan, S., Hütter, J., Schramm, M., & Flamme, I. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)00862-8 · Cited by 165
Kajimura, S., Aida, K., & Duan, C. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.3.1142-1155.2006 · Cited by 164
E3 ligase ligand chemistries: from building blocks to protein degraders
Sosič, I., Bricelj, A., & Steinebach, C. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00148a · Cited by 163
Constitutive and inducible expression and regulation of vascular endothelial growth factor
Xie, K., Wei, D., Shi, Q., & Huang, S. (2004) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2004.04.003 · Cited by 163
“This interaction causes HIF-1 to become ubiquitylated and targeted to the proteasome, where it is degraded [236–238].”
BackgroundHIF-1: master and commander of the hypoxic world
Mazure, N. M., Brahimi-Horn, M. C., Berta, M., Benizri, E. I., Bilton, R. L., Dayan, F., Ginouvès, A., Berra, E., & Pouysségur, J. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.04.022 · Cited by 181
HIF-1α in Epidermis: Oxygen Sensing, Cutaneous Angiogenesis, Cancer, and Non-Cancer Disorders
Rezvani, H. R., Ali, N., Nissen, L. J., Harfouche, G., de Verneuil, H., Taïeb, A., & Mazurier, F. (2011) · Journal of Investigative Dermatology · doi:10.1038/jid.2011.141 · Cited by 171
“The hydroxylation of HIF-1a mediated by prolyl hydroxylases is a prerequisite for the association of HIF-1a with von Hippel–Lindau (Maxwell et al., 1999; Cockman et al., 2000; Kamura et al., 2000; Ohh et al., 2000).”
BackgroundNotch increases the shedding of HB-EGF by ADAM12 to potentiate invadopodia formation in hypoxia
Díaz, B., Yuen, A., Iizuka, S., Higashiyama, S., & Courtneidge, S. A. (2013) · Journal of Cell Biology · doi:10.1083/jcb.201209151 · Cited by 161
“Because the regulation of HIF-1 is mainly posttranscriptional (Ohh et al., 2000), we analyzed the expression of HIF-1 and ADAM12 by immunohistochemistry on lung tumor sections.”
Pyruvate Dehydrogenase Kinases: Therapeutic Targets for Diabetes and Cancers
Jeoung, N. H. (2015) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2015.39.3.188 · Cited by 161
“In the normoxic condition, Hif-1 α is lowered by an ubiquitin-dependent proteasomal degradation induced by the von Hippel-Lindau protein, resulting in the prevention of heterodimerization with Hif-1 β [25].”
BackgroundMechanisms of mTOR inhibitor resistance in cancer therapy
Carew, J. S., Kelly, K. R., & Nawrocki, S. T. (2011) · Targeted Oncology · doi:10.1007/s11523-011-0167-8 · Cited by 161
S-Nitrosothiols signal hypoxia-mimetic vascular pathology
Palmer, L. A., Doctor, A., Chhabra, P., Sheram, M. L., Laubach, V. E., Karlinsey, M. Z., Forbes, M. S., Macdonald, T., & Gaston, B. (2007) · Journal of Clinical Investigation · doi:10.1172/jci29444 · Cited by 161
“In BPAECs transiently transfected with wildtype pVHL or with cysteine-to-serine mutants C77S, C162S, or C77S/C162S, mutation of C162 eliminated SNOAC-induced pVHL S-nitrosylation (Figure 5G), consistent with evidence that C162 is required for pVHL to bind elongin C and ubiquitinate HIF 1α (46).”
Hypoxia-Inducible Factor-1α Expression in Macrophages Promotes Development of Atherosclerosis
Aarup, A., Pedersen, T. X., Junker, N., Christoffersen, C., Bartels, E. D., Madsen, M., Nielsen, C. H., & Nielsen, L. B. (2016) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.116.307830 · Cited by 151
Influence of hypoxia and neoangiogenesis on the growth of pancreatic cancer.
Duffy, J. P., Eibl, G., Reber, H. A., & Hines, O. J. (2003) · Molecular Cancer · doi:10.1186/1476-4598-2-12 · Cited by 185
“The VHL protein contains a binding site in the oxygen-dependent degradation domain (ODD) of HIF-1α between amino acids 401–603 [35–37].”
BackgroundMack, F. A., Rathmell, W. K., Arsham, A. M., Gnarra, J., Keith, B., & Simon, M. C. (2003) · Cancer Cell · doi:10.1016/s1535-6108(02)00240-4 · Cited by 160
“Mutations within the β-domain of pVHL disrupt its interaction with HIF-α subunits leading to constitutive HIF-α stabilization and HIF activity (Cockman et al. 2000; Ohh et al. 2000).”
BackgroundNag, A., Bondar, T., Shiv, S., & Raychaudhuri, P. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.20.6738-6747.2001 · Cited by 160
Role of ETS Transcription Factors in the Hypoxia-Inducible Factor-2 Target Gene Selection
Aprelikova, O., Wood, M., Tackett, S., Chandramouli, G. V. R., & Barrett, J. C. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3345 · Cited by 155
Bento, C. F., & Pereira, P. (2011) · Diabetologia · doi:10.1007/s00125-011-2191-8 · Cited by 159
Targeting the Metabolic Microenvironment of Tumors
Bailey, K. M., Wojtkowiak, J. W., Hashim, A. I., & Gillies, R. J. (2012) · Advances in Pharmacology · doi:10.1016/b978-0-12-397927-8.00004-x · Cited by 154
“Under normoxic conditions, HIF1a is inactivated via proteasomal degradation, regulated by the VHL ubiquitin ligase (Jaakkola et al., 2001; Ohh et al., 2000).”
BackgroundLi, Z., Na, X., Wang, D., Schoen, S. R., Messing, E. M., & Wu, G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m108269200 · Cited by 156
HYPOXIA‐INDUCED ERYTHROPOIETIN PRODUCTION: A PARADIGM FOR OXYGEN‐REGULATED GENE EXPRESSION
Stockmann, C., & Fandrey, J. (2006) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2006.04474.x · Cited by 153
Niu, X., Zhang, T., Liao, L., Zhou, L., Lindner, D. J., Zhou, M., Rini, B., Yan, Q., & Yang, H. (2012) · Oncogene · doi:10.1038/onc.2011.266 · Cited by 155
“This complex targets the a subunits of the heterodimeric transcription factor hypoxia-inducible factor (HIF) for ubiquitylation and proteasome-mediated degradation (Ohh et al., 2000).”
BackgroundKatschinski, D. M., Le, L., Heinrich, D., Wagner, K. F., Hofer, T., Schindler, S. G., & Wenger, R. H. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m110377200 · Cited by 157
Melville, M. W., McClellan, A. J., Meyer, A. S., Darveau, A., & Frydman, J. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.9.3141-3151.2003 · Cited by 155
Fish, J. E., Matouk, C. C., Yeboah, E., Bevan, S. C., Khan, M., Patil, K., Ohh, M., & Marsden, P. A. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m608318200 · Cited by 155
Self-citationExploiting the Ref-1-APE1 node in cancer signaling and other diseases: from bench to clinic
Shah, F., Logsdon, D. P., Messmann, R. A., Fehrenbacher, J. C., Fishel, M. L., & Kelley, M. R. (2017) · npj Precision Oncology · doi:10.1038/s41698-017-0023-0 · Cited by 162
Zhang, J.-G., Metcalf, D., Rakar, S., Asimakis, M., Greenhalgh, C. J., Willson, T. A., Starr, R., Nicholson, S. E., Carter, W., Alexander, W. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.231486498 · Cited by 155
Hypoxia increases sirtuin 1 expression in a hypoxia-inducible factor-dependent manner
Chen, R., Dioum, E. M., Hogg, R. T., Gerard, R. D., & Garcia, J. A. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.175414 · Cited by 155
The metabolic basis of kidney cancer
Linehan, W. M., & Ricketts, C. J. (2013) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2012.06.002 · Cited by 144
Kamura, T., Burian, D., Yan, Q., Schmidt, S. L., Lane, W. S., Querido, E., Branton, P. E., Shilatifard, A., Conaway, R. C., & Conaway, J. W. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103093200 · Cited by 154
Hypoxia affects mesoderm and enhances hemangioblast specification during early development
Ramírez-Bergeron, D. L., Runge, A., Dahl, K. D. C., Fehling, H. J., Keller, G., & Simon, M. C. (2004) · Development · doi:10.1242/dev.01310 · Cited by 152
“Under normoxic conditions, the HIFα subunits HIF1α, HIF2α (EPAS) and HIF3α are targeted for proteasome degradation by the von Hippel-Lindau (VHL) protein (Cockman et al., 2000; Maxwell et al., 1999; Ohh et al., 2000).”
BackgroundLi, Q. F., Wang, X. R., Yang, Y. W., & Lin, H. (2006) · Cell Research · doi:10.1038/sj.cr.7310072 · Cited by 169
Hypoxia-inducible factors as molecular targets for liver diseases
Ju, C., Colgan, S. P., & Eltzschig, H. K. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-016-1408-1 · Cited by 157
“The critical step in α -subunit degradation is the hydroxylation of proline residues by prolyl hydroxylase domain enzymes (PHD1-3), allowing recognition of the α -subunit by the von Hippel-Lindau (VHL) E3 ubiquitin ligase complex and subsequent proteasomal degradation [2, 3].”
HIF‐1‐dependent transcriptional activity is required for oxygen‐mediated HIF‐1α degradation
Berra, E., Richard, D. E., Gothié, E., & Pouysségur, J. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)02159-7 · Cited by 149
Hypoxia-inducible factor 1α is closely linked to an aggressive phenotype in breast cancer
Yamamoto, Y., Ibusuki, M., Okumura, Y., Kawasoe, T., Kai, K., Iyama, K., & Iwase, H. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9742-1 · Cited by 151
The VHL tumor suppressor and HIF: insights from genetic studies in mice
Kapitsinou, P. P., & Haase, V. H. (2008) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402313 · Cited by 151
Regulatory role of HIF-1α in the pathogenesis of age-related macular degeneration (AMD)
Arjamaa, O., Nikinmaa, M., Salminen, A., & Kaarniranta, K. (2009) · Ageing Research Reviews · doi:10.1016/j.arr.2009.06.002 · Cited by 164
An E3 ligase guide to the galaxy of small-molecule-induced protein degradation
Jevtić, P., Haakonsen, D. L., & Rapé, M. (2021) · Cell Chemical Biology · doi:10.1016/j.chembiol.2021.04.002 · Cited by 143
Vorrink, S. U., & Domann, F. E. (2014) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2014.05.001 · Cited by 156
“PHD enzymes hydroxylate HIF-1α in an oxygen-dependent manner at two proline residues, P564 and P402, which leads to subsequent ubiquitination by von Hippel-Lindau (VHL) proteins and ultimately proteasomal degradation (Ohh et al., 2000; Kewley et al., 2004; Dery et al., 2005).”
BackgroundHIF-1 and hypoxic response: the plot thickens
Poellinger, L., & Johnson, R. S. (2003) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2003.12.006 · Cited by 161
Genotype-phenotype correlation in von Hippel-Lindau syndrome
Friedrich, C. A. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.7.763 · Cited by 150
Hypoxia Induced ER Stress Response as an Adaptive Mechanism in Cancer
Chipurupalli, S., Kannan, E., Tergaonkar, V., D’Andrea, R. J., & Robinson, N. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030749 · Cited by 161
“VHL recruits a ubiquitin ligase protein complex consisting of elongin B, elongin C, and cullin, which ultimately results in ubiquitination and degradation of HIF-1α by the 26S proteasome [36,37].”
BackgroundBishop, T., Lau, K. W., Epstein, A. C. R., Kim, S. K., Jiang, M., O'Rourke, D., Pugh, C. W., Gleadle, J. M., Taylor, M. S., Hodgkin, J., et al. (2004) · PLoS Biology · doi:10.1371/journal.pbio.0020289 · Cited by 145
“To date, the best-understood function of VHL is as a ubiquitin ligase that affects oxygen-dependent proteolytic targeting of the a subunits of hypoxia-inducible factor (HIF) (Maxwell et al. 1999; Ohh et al. 2000).”
Zatyka, M., da Silva, N. F., Clifford, S. C., Morris, M. R., Wiesener, M. S., Eckardt, K., Houlston, R. S., Richards, F. M., Latif, F., & Maher, E. R. (2002) · PubMed · doi:10.25405/ncl.34582002 · Cited by 171
Effects of hypoxia on tumor metabolism
Kim, J., Gao, P., & Dang, C. V. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9060-4 · Cited by 166
Srinivas, V., Leshchinsky, I., Sang, N., King, M. P., Minchenko, A., & Caro, J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.c100177200 · Cited by 143
Babon, J. J., Sabo, J. K., Zhang, J.-G., Nicola, N. A., & Norton, R. S. (2009) · Journal of Molecular Biology · doi:10.1016/j.jmb.2009.01.024 · Cited by 144
Harada, H., Hiraoka, M., & Kizaka‐Kondoh, S. (2002) · PubMed · Cited by 160
Papillary renal cell carcinoma: A review of the current therapeutic landscape
Courthod, G., Tucci, M., Maïo, M. D., & Scagliotti, G. V. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.05.008 · Cited by 158
“[6] Ohh M, Park CW, Ivan M, Hoffman MA, Kim TY, Huang LE, et al.”
BackgroundLaw, S. H. W., Wu, R. S. S., Ng, P. K., Yu, R. M. K., & Kong, R. Y. C. (2006) · BMC Molecular Biology · doi:10.1186/1471-2199-7-15 · Cited by 145
“Hydroxylation of these proline residues increases the affinity of HIF-1α for the Von Hippel Lindau tumor suppressor (VHL) protein, which is part of an E3 ubiquitin-ligase complex that targets the protein for proteasomal degradation [8].”
Review: Cellular Substrates of the Eukaryotic Chaperonin TRiC/CCT
Dunn, A. Y., Melville, M. W., & Frydman, J. (2001) · Journal of Structural Biology · doi:10.1006/jsbi.2001.4380 · Cited by 145
Hypoxia-induced genetic instability—a calculated mechanism underlying tumor progression
Huang, E. L., Bindra, R. S., Glazer, P. M., & Harris, A. L. (2006) · Journal of Molecular Medicine · doi:10.1007/s00109-006-0133-6 · Cited by 159
The von Hippel–Lindau Chuvash mutation promotes pulmonary hypertension and fibrosis in mice
Hickey, M. M., Richardson, T., Wang, T., Mosqueira, M., Arguiri, E., Yu, H., Yu, Q.-C., Solomides, C. C., Morrisey, E. E., Khurana, T. S., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci36362 · Cited by 141
Redox Regulation via Glutaredoxin-1 and Protein S -Glutathionylation
Matsui, R., Ferrán, B., Oh, A., Croteau, D., Shao, D., Han, J., Pimentel, D. R., & Bachschmid, M. M. (2020) · Antioxidants and Redox Signaling · doi:10.1089/ars.2019.7963 · Cited by 153
Sang, N., Fang, J., Srinivas, V., Leshchinsky, I., & Caro, J. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.9.2984-2992.2002 · Cited by 143
The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy
Clark, P. E. (2009) · Kidney International · doi:10.1038/ki.2009.296 · Cited by 156
Anti-angiogenic therapy: Rationale, challenges and clinical studies
Longo, R., Sarmiento, R., Fanelli, M., Capaccetti, B., Gattuso, D., & Gasparini, G. (2002) · Angiogenesis · doi:10.1023/a:1024532022166 · Cited by 170
Hypoxia: the tumor's gateway to progression along the angiogenic pathway
Brahimi‐Horn, C., Berra, E., & Pouysségur, J. (2001) · Trends in Cell Biology · doi:10.1016/s0962-8924(01)02126-2 · Cited by 153
Clifford, S. C., Astuti, D., Hooper, L., Maxwell, P. H., Ratcliffe, P. J., & Maher, E. R. (2001) · Oncogene · doi:10.1038/sj.onc.1204602 · Cited by 156
“…complex binds the oxygen dependent destruction domain of HIFa subunits through the b-domain of pVHL, with pVHL acting as the recognition component of the E3 ubiquitin ligase complex mediating HIF-a destruction (Cockman et al., 2000; Ohh et al., 2000; Tanimoto et al., 2000; Kamura et al., 2000).”
BackgroundMethodInfluentialPhysiology and pathophysiology of renal erythropoietin-producing cells
Shih, H., Wu, C., & Lin, S. (2018) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2018.03.017 · Cited by 154
Wang, Y., Roche, O., Xu, C., Moriyama, E. H., Heir, P., Chung, J., Roos, F. C., Chen, Y., Finak, G., Milosevic, M., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1112129109 · Cited by 137
“of a failure to form the E3 ligase ECV) (29) showed markedly increased CAV1 mRNA and protein levels in comparison with 786-VHL(WT) and 786-VHL(L188V) (amutant that has retained E3 ligase function to degrade HIFα) (Fig.”
BackgroundSelf-citation
Metadata
- Authors
- Ohh, M., Park, C. W., Ivan, M., Hoffman, M. A., Kim, T.-Y., Huang, L. E., Pavletich, N., Chau, V., & Kaelin, W. G.
- Affiliations
- Brigham and Women's Hospital (US)
- Memorial Sloan Kettering Cancer Center (US)
- Pennsylvania State University (US)
- Corresponding author
- Kaelin, William G.
- Venue
- Nature Cell Biology
- Published
- 2000-06-09
- Volume
- 2
- Issue
- 7
- Pages
- 423-427
- ISSN
- 1465-7392 (ISSN-L)
- 1476-4679
- OpenAlex
- W2147718842
- Cited by
- 1,577
- References
- 21
- Citations by year
- 2026: 23 · 2025: 36 · 2024: 46 · 2023: 36 · 2022: 49 · 2021: 56 · 2020: 59 · 2019: 45 · 2018: 40 · 2017: 50 · 2016: 52 · 2015: 45 · 2014: 62 · 2013: 66 · 2012: 70
- FWCI
- 33.78
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Cell Biology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Ear and Head Tumors
- Keywords
- von Hippel-Lindau protein, hypoxia-inducible factor, ubiquitination, F-box protein, protein-protein interaction, alpha-domain, von Hippel-Lindau disease, tumor suppressor, vascular tumors, E3 ubiquitin ligase
- MeSH terms
- Elongin, Cell Extracts, Deferoxamine, DNA-Binding Proteins, HeLa Cells, Humans, Ligases, Mutation, Nuclear Proteins, Oxygen, Protein Binding, Protein Processing, Post-Translational, Proteins, Transcription Factors, Transfection, Tumor Cells, Cultured, Ubiquitins, Protein Structure, Tertiary, Tumor Suppressor Proteins, Ubiquitin-Protein Ligases, Hypoxia-Inducible Factor 1, Von Hippel-Lindau Tumor Suppressor Protein, Hypoxia-Inducible Factor 1, alpha Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.